Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodriguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2018) 132 (25): 2656–2669.

https://doi.org/10.1182/blood-2018-03-836718

Published: 2018

Includes: Supplemental data

Journal Articles

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Jessie Bourcier, MD, Antoine Bonnet, MD, Géraldine Descamps, PhD, Carolane Seiller, Cyrille Touzeau, MD PhD, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2018) 132 (Supplement 1): 953.

https://doi.org/10.1182/blood-2018-99-109987

Published: 2018

Journal Articles

No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide

Alice Garnier, MD, Thierry Guillaume, MD PhD, Pierre Peterlin, Amandine Le Bourgeois, PhD, Alix Duquesne, Marion Eveillard, PharmD, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Antoine Bonnet, MD, Steven LE Gouill, MD PhD, Philippe Moreau, Marie C Bene, PharmSci, PhD, Patrice Chevallier, MD

Blood (2018) 132 (Supplement 1): 4577.

https://doi.org/10.1182/blood-2018-99-112453

Published: 2018

Journal Articles

Influence of Donor Type (sibling vs matched-unrelated donor vs haplo-identical donor vs cord blood) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies

Louise Bouard, Thierry Guillaume, MD PhD, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Alix Duquesne, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Antoine Bonnet, MD, Steven LE Gouill, MD PhD, Philippe Moreau, Marie C Bene, PharmSci, PhD, Patrice Chevallier, MD

Blood (2018) 132 (Supplement 1): 3451.

https://doi.org/10.1182/blood-2018-99-112369

Published: 2018

Journal Articles

Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study

Blood (2018) 132 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2018-99-111694

Published: 2018

Journal Articles

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Antoine Bonnet, MD, Jessie Bourcier, MD, Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Philippe Moreau, MDPhD, Steven Le Gouill, MDPhD, Catherine Pellat-Deceunynck, PhD, Cyrille Touzeau, MD PhD, Martine Amiot, PhD

Blood (2017) 130 (Supplement 1): 4383.

https://doi.org/10.1182/blood.V130.Suppl_1.4383.4383

Published: 2017

Journal Articles

Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013

Inès Boussen, Caroline Algrin, MD, Julien Rossignol, MD, Eric Durot, MD, Sarah Guenounou, Antoine Bonnet, Jeremy Delage, MD, Emmanuel Gyan, MD PhD, Fontanet Bijou, MD, Noel Milpied, MD, Adrien Chauchet, MD, Adrien Tempescul, MD, Gandhi Damaj, MD, Arnaud Jaccard, MD PhD, Jerome Cornillon, MD, Norbert Ifrah, Veronique Leblond, Sylvain Choquet, MD

Blood (2016) 128 (22): 4230.

https://doi.org/10.1182/blood.V128.22.4230.4230

Published: 2016

Journal Articles

EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I–associated adult T-cell leukemia/lymphoma

Georges Moarbess, Hiba El-Hajj, Youmna Kfoury, Marwan E. El-Sabban, Yves Lepelletier, Olivier Hermine, Carine Deleuze-Masquéfa, Pierre-Antoine Bonnet, Ali Bazarbachi

Blood (2008) 111 (7): 3770–3777.

https://doi.org/10.1182/blood-2007-11-121913

Published: 2008

NARROW

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide

Influence of Donor Type (sibling vs matched-unrelated donor vs haplo-identical donor vs cord blood) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies

Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013

EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I–associated adult T-cell leukemia/lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only